We would love to hear your thoughts about our site and services, please take our survey here.
HTtps://gov.vitadao.com/t/vdp-117-magnaetus-therapeutics/1417
Global online DAO approves launch and financing of MatrixBio to optimal drug candidates for age-related diseases.
VitaDAO, the global online community driving early-stage longevity research through innovative funding collaborations has announced the launch of its very first biotech company – Matrix Biosciences. This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, PhD, Co-Chair of the University of Rochester’s Aging Research Center.
htTps://longevity.technology/news/vitadao-community-launches-its-first-biotech-company/
Material news!!!??? Gla ;-)
2023 Healthy Longevity Global Innovator Summit
09/26/2023 8:00am
The evolving role of generative artificial intelligence in healthcare was front and center at the annual Healthy Longevity Global Innovator Summit, with experts expounding on its potential to help people live longer, healthier lives. Delivering the conference keynote was Peter Lee, Microsoft Corporate Vice President of Research and Incubations, who had a personal link to the topic of AI and medicine.
.........................
Developing therapeutic agents reverse ageing and metabolic decline
Cary Depel; Paul Baldock; Guy Barry | Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences
Competition Sponsor: US National Academy of Medicine
Awardee Year: 2023
Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.
To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.
Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.
htTps://healthylongevitychallenge.org/winners/developing-therapeutic-agents-reverse-ageing-and-metabolic-decline/
hTtps://healthylongevitychallenge.org/event/2023-healthy-longevity-global-innovator-summit/
Fully funded until March 2025 and so amazed to see this fall to sub 2p, although presents a great opportunity to accumulate cheap shares with undoubted multi-bag potential in the coming weeks and months as good news is delivered. Gla holders..:-)
My £3k top up at 1.55p is showing as a sell. Gla :-)
Plenty of material news to get the sp heading North expected in the coming weeks.
Eric confirmed in his recent interview they're in negotiations for two new non-dilutive funding grants expected to provide funding for an additional 3 years for 80% of their R&D, news if which could drop at anytime, followed by the Final Reports from their 4 academic collaborations which should be very well received.
Gla holders, the current bargain low offers tremendous UPside as progress is made and every chance of a major investor or JV partner in the Pipeline, given the huge promise of Sirt6's potency and importance in longevity, healthspan and multiple disease targets. ;-)
28/9/23
The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.
......
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
28/9/23 Half Year Report
-- The Group has expanded its intellectual property portfolio through a provisional patent application focussing on the ability to edit its SIRT6 gene. If granted, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy.
.......
1.20230018934
METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS
US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688
Applicant GENFLOW BIOSCIENCES SRL
Inventor Eric LEIRE
Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.
Perenco’s recent success in a marginal field in shallow water, has many similarities to Njom-3. Gla ;-)
Cameroon
June 29, 2023
Perenco has completed the South Kole Marine oil development 50 km offshore Cameroon.
PARIS, France — Perenco has completed the South Kole Marine oil development 50 km offshore Cameroon.
The marginal field, discovered by a previous operator in the 1980s, is in 30 m to 50 m water depth.
Following an eight-month program—which according to the company involved innovations in terms of well architecture, pipelay and the type of platforms installed—production is currently above 3,800 bbl/d.
Earlier this month, Perenco signed a new 20-year production sharing contract with Société Nationale des Hydrocarbures for continued development of the Rio del Rey Basin, also offshore Cameroon.
Ps Dissoni is North of Njom-3....:-)
The area has been explored by Pecten (Shell) and ELF (now Total) since the 1960s with several discoveries made within an earlier licence. As a result, the current Thali Block includes the Total’s Njonji-1 discovery well drilled in 2008 which encountered 35° API oil in several shallow stacked Pliocene sands. The Njonji-2, appraisal well confirmed the discovery in 2010, but was deemed uncommercial at that time before any testing, leading to Total’s strategic exit and sale of its entire Cameroon portfolio to Perenco in 2011. Perenco put the Dissoni field into production, immediately to the north of the current Thali Block, before relinquishing the rest of the licence. Tower then applied for, and were awarded the Thali Block in 2015. Since then, they have reprocessed the 3D seismic originally acquired in 1991 over part of the Block, including over the Njonji discovery. This new data has provided a more accurate definition of the Njonij structure, its closures and their commercial potential. Tower is now seeking a strategic partner to join them in funding the planned Njonji-3 appraisal well to flow test the oil in the Pliocene sands, followed by a rapid development. The Njonji-3 well is drill-ready. All long-lead items have been purchased, the site survey is completed and rig contract under negotiation.
An independent CPR completed by Oilfield International in October 2018 has confirmed an initial two-phase development could exploit the ‘mean’ 18 MMbbls contingent recoverable resources (and upside of 34+ MMbls rec) from the three primary Pliocene reservoir sands in the northern Njonji closure above 1,100 metres. Follow-on drilling could then exploit a gross ‘mean’ prospective resources of 20 MMbbls in the southern closure, which has an upside potential of 74+ MMbbls rec.
The economics show a four well ‘stand-alone’ development of just the contingent Northern Njonji resource potential is commercial. This could produce 8,000 bopd, with the proximity to local infrastructure providing rapid cash flow with recovery of exploration costs under the PSC from potential annual cash flows of >$100 million and an EMV10 of US$118 million. An additional EMV10 of US$82 million is calculated for the development of the prospective Southern Njonji resource potential. Substantial 100+ MMboe potential upside remains undrilled in the Dissoni South and Idenao East analogue prospects in the Block, immediately south of Perenco’s Dissoni field.
The undrilled deep exploration play potential in the Thali PSC offers equally large resource upside already proven on trend in the deeper Rio del Rey Basin. In addition to the Alba and Zafiro fields, the Isongo fields lie on trend to the south east of the Thali Block.
Perenco’s Dissoni oil producing block is south of Thali, and it was Total who made the discovery in 2008, but deemed the volume weren't big enough for a Major and so Total relinquished the block and Perenco took ownership. Perenco has never drilled Thali and they in turn relinquished the block around 2015, as they were so busy with the rest of their numerous prospects in the Rio Del Rey basin, and that’s when Tower took ownership....35m plus barrel potential is peanuts for Total who are only interested in mega discoveries similar to their current success offshore Namibia, but 35m barrels for Tower would be well and truly transformational. Gl :-)
Consensus recommendation to immediately expand research on extending healthy human lifespans.
The Longevity Escape Velocity Foundation (LEVF) has welcomed the publication today of the Dublin Longevity Declaration. This Declaration calls on governments, funding agencies and the public to intensify their support for the promising interventional ideas that exist to fight age-related suffering and disease, and for the generation and exploration of further ways to extend healthy lifespan.
hTtps://longevity.technology/news/scientific-leaders-issue-global-dublin-longevity-declaration/amp/
Any large buy would take time to fill, especially a huge one for 117,500,000, and then gets reported after close when the broker balances his book for all trades that day, sometimes it and take several days before it's reported depending on liquidity. Gl ;-)
RNS Number : 5779O
Tower Resources PLC
04 October 2023
Logo Description automatically generated
4 October 2023
Tower Resources plc
("Tower" or the "Company")
Share Issuance to Energy Exploration Capital Partners LLC
Tower Resources plc (AIM: TRP), the Africa-focused energy company, announces that Energy Exploration Capital Partners, LLC ("EECP" or the "Placee"), in accordance with the terms of the investment deed (the "Deed") announced to the market on 16 January 2023, has requested that the Company issue 317,601,462 ordinary shares of 0.001p each ("Placing Shares") to the Placee. The purchase price of 0.04p per share, set by mutual agreement given that the market price remains below the Floor Price set out in the Deed, for the settlement amount of US$153,846.15 including fees, was previously prepaid by the Placee.
Application for Admission:
Application has been made for the Placing Shares to be admitted to trading on AIM with admission expected to take place on or around 9 October 2023. The Placing Shares will rank pari passu in all respects with all existing ordinary shares in the Company.
Total Voting Rights:
Following Admission of the Placing Shares, the Company's enlarged issued share capital will comprise 8,761,582,484 ordinary shares with voting rights. There are no Shares currently held in treasury. This figure of 8,761,582,484 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Genflow could be on many radars, given how many leading scientists believe Sirt6 is so fundamental and tought to be the most potent and important gene for longevity, healthspan and multiple disease targets, and so every chance of a Major investor and or JV partner in the not too distant...in the meantime, there's plenty of material news to add significant value in the pipeline that could land at anytime. Gla :-)
All bodes well...Gla :-)
Perfectly poised!!! Gla :-)
Mon, 2 October 2023
Crypto's top CEOs are playing a pivotal role in driving funding for longevity research and anti-ageing technology, a leading scientist has claimed.
Longevity Escape Velocity Foundation president Aubrey de Grey, shared his insights in a recent episode of Yahoo Finance's The Crypto Mile.
De Grey highlighted the crypto community's support for both non-profit initiatives and investment ventures in the longevity sector.
He said that influential figures like Hex's Richard Heart, ethereum's (ETH-USD) Vitalik Buterin, Coinbase's (COIN) Brian Armstrong, and Cardano's Charles Hoskinson are engaged in both non-profit initiatives and investment ventures within the longevity sector.
"Brian Armstrong, co-founder of Coinbase, created a company called New Limited, which he put north of $50m in to, and Cardano's Charles Hoskinson has created an anti-ageing clinic in Wyoming," de Gray added.
The longevity scientist further noted that on the non-profit side of anti-ageing research, several donors from the cryptocurrency sector have contributed significantly.
"The biggest and most conspicuous example in that regard is the Hex community, the community of people who made their money out of the cryptocurrency called Hex, led by Richard Heart," said De Grey.
"Richard had this wonderful idea a few years ago to encourage his flock to donate to the SENS Research Foundation, and that worked out very well to the tune of $27m."
Investment from sovereign wealth funds and the private sector
According to a report, the longevity sector is experiencing increasing momentum and is projected to reach a market size of $44.2bn by 2030, with a compound annual growth rate (CAGR) of 6.1% from 2021 to 2030.
Capital inflow into the field has surged, with notable contributions from individuals like Amazon's Jeff Bezos and substantial investments from sovereign wealth funds, particularly from the Middle East and Asia. De Grey pointed out that this influx of funding began around 2017 when private sector involvement was minimal, but it has grown exponentially in recent years.
De Grey underscored how sovereign wealth funds, especially from the Middle East and the Far East, have started to get involved. Saudi Arabia's goal of investing $1bn annually, has created a ripple effect, inspiring other nations to follow suit.
Tower Resources PLC (AIM:TRP) told investors that it is “currently at a very advanced stage of negotiations” for a rig contract for the NJOM-3 well in Cameroon and expects it will be concluded soon.
“The rig contract is the critical next step in finalising the timing of the well, and so everything else depends on it and naturally follows it,” Tower chief executive Jeremy Asher said in the company’s interim results statement.
“The rig contract will still leave a wide operational tolerance for the well spud date, based on the timing of the current operations which the rig is undertaking, but it will be a firm commitment between the rig owner and the company.
“We are working with the Ministry of Mines, Industry and Technological Development on documenting the promised license extension to reflect the rig contract and especially the operational tolerances that it will contain.
“We expect the rig contract to be conditional on the formal documentation of the license extension, and although it is no longer feasible to spud the well in 2023, we are still hoping to be able to spud the well in the first half of 2024.”
In terms of the financial results, the pre-revenue exploration company had just shy of US$1 million of cash at the end of June and it is advancing a farm-out process in order to fund its share of costs for the NJOM-3 operations.
Asher added: “Our objective is still to farm out a minority share of the license interest, which should provide most or all of the remaining funding required for the well.
“The funding requirement was most recently estimated at US$13.4 million, though this estimate is always subject to change.
“We are discussing this with multiple parties, and one discussion is now at a very advanced stage.
“Any funding agreement will likely depend on the rig contract and the license extension documentation being completed.
“We are also still discussing credit facilities with the local Cameroon banks, although the difficulties of reconciling their requirements with a farm-out type of funding agreement have led us to prioritise the farm-out discussions over the bank discussions for the time being.”
We await the next UPdate from Cameroon, expected soon as intimated by JA in today's interview, the news from South Africa is excellent for imminent for TotalEnergies plans to develop and produce the two mega gas discoveries that straddle Tower's South Africa acerage...the greenlight will be highly significant for Tower. Gla :-)
South Africa’s Luiperd-Brulpadda Gas Fields Represent Huge Opportunities; We Must Not Let Them Pass Us By
27/6/23
By NJ Ayuk, Executive Chairman, African Energy Chamber
....
Potential Power Generation
For decades, oil and gas exploration in South Africa had yielded what our report describes as “scattered and sporadic success.”
But all of that changed in 2019 when Total (now TotalEnergies) announced its Brulpadda discovery, followed by the Luiperd discovery one year later. Brulpadda Field is estimated to hold at least 275 million barrels of oil equivalent (MMboe), and Luiperd’s estimated reserves are approximately 340 MMboe, with 70% gas each in both discoveries.
These numbers are huge and among the largest made in our continent in their respective years.
“Brulpadda accounted for 10% of the overall discovered volumes in Africa in 2019, and Luiperd accounted for a whopping 80% of the overall volumes discovered in 2020,” our report notes.
When the Brulpadda and Luiperd fields come online, their cumulative average output is estimated to be around 35,000 barrels per day of liquids and about 100,000 barrels of oil equivalent per day (boepd) of natural gas.
htTps://www.africa.com/south-africas-luiperd-brulpadda-gas-fields-represent-huge-opportunities-we-must-not-let-them-pass-us-by/
0 0 0
CAPE TOWN, Oct 2 (Reuters) - South Africa's environment ministry has given the go-ahead for TotalEnergies (TTEF.PA) to drill offshore for gas and oil, after rejecting an appeal from more than a dozen individuals and lobby groups who intend challenging the decision.
The appeal to stop TotalEnergies from drilling in Block 5/6/7 off the Cape coast was the latest in a series of actions seeking to halt energy companies exploring for new offshore discoveries at the foot of Africa.
TotalEnergies, which discovered two massive gas fields off South Africa in 2019 and 2020, did not immediately respond to a request for comment. Its area of interest in the block covers some 10,000 square km and is located roughly between Cape Town and Cape Agulhas, some 60 km from the coast at its closest point and 170 km at its furthest, in water depths between 700 metres and 3,200 metres.
TotalEnergies, the operator with a 40% stake, and partners Shell (SHEL.L), also with 40%, and national oil company PetroSA holding the remaining 20%, propose drilling up to five exploration wells in the block.
The last time the sp was at this low was 6 months ago, a Company Update was released followed by the Final Results which saw the stellar rise in sp from sub 2p to 5p plus, and so let's see what happens on the release of the Half Year Results expected end of this month, which no doubt will have substantial detail on proceedings, including the status of the planned Werner Syndrome, accelerated clinical trials and maybe a further UPdate on the two non-dilutive research grants mentioned by Eric in his interview, which will see Genflow fully cashed for 80% of their R&D well into 2026. Gla Holders. Gla Holders...Fill ya Boots at this rockbottom bargain low.....this will bounce big in the coming days imho.....On and eventually UP!!! ;-)